LIVE
GILD
Gilead Sciences, Inc. · Healthcare
$123.76
-5.16% this month
VERSUS
⟷
COMPARE
ABBV
AbbVie Inc. · Healthcare
$216.49
+1.28% this month
Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
GILD
3
ABBV
2
Comparison scoreboard
GILD LEADS 3/5AI Score
GILD 41.3
ABBV ✓52.0
1Y Return
GILD +14.59%
ABBV ✓+16.72%
Fwd P/E
GILD ✓12.80
ABBV 13.32
Target Up.
GILD ✓+27.32%
ABBV +17.12%
Op. Margin
GILD ✓39.28%
ABBV 32.16%
Metrics last refreshed: 6/22/2026
Quick take
GILD vs ABBV Stock Comparison: AI Score, Valuation, Performance and Upside
Gilead and AbbVie are both large-cap biopharma income investments with dominant franchises (Biktarvy HIV and Skyrizi/Rinvoq immunology respectively) and substantial dividends. They operate in completely different therapeutic areas with different pipeline risks and revenue profiles. Gilead's antiviral dominance is more concentrated but highly durable; AbbVie is successfully replacing Humira with its successor immunology drugs while Botox diversifies into consumer healthcare.
GILD vs ABBV is a comparison between the antiviral market leader with oncology diversification (Gilead) and the post-Humira immunology giant with aesthetics diversification (AbbVie) — both pay significant dividends from large franchise revenues and are investing in pipeline diversification to sustain long-term earnings.
Live analysis · updated 6/22/2026
GILD holds the edge across 3 of 5 key metrics in this comparison. ABBV has delivered stronger 1-year price return (+16.72% vs +14.59%), though GILD trades at the lower forward P/E (12.80x vs 13.32x). On fundamentals, ABBV is growing revenue faster (12.40%), while GILD maintains the higher operating margin (39.28%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for GILD (+27.32%) than for ABBV (+17.12%).
Normalized 1Y performance
GILD
ABBV
Recent returns
GILD
ABBV
Analyst price targets & sentiment
GILD · 26 analysts
STRONG BUYHOLDSTRONG SELL
Buy (1.9/5.0)
Price target range
analyst low$92.00
analyst mean$157.57
current price$123.76
+27.3% upside to analyst mean
ABBV · 27 analysts
STRONG BUYHOLDSTRONG SELL
Buy (2.0/5.0)
Price target range
analyst low$170.00
analyst mean$253.55
current price$216.49
+17.1% upside to analyst mean
Who should consider this stock?
GILD may suit investors who:
- →prefer an antiviral-dominant biopharma with Biktarvy HIV franchise providing extremely durable recurring revenue
- →value Trodelvy ADC and CAR-T oncology pipeline as diversification into high-growth cancer treatment markets
- →want dividend income from HIV antiviral cash flows with potential upside from MASH and oncology pipeline catalysts
- →are comfortable with long-acting injectable HIV competition and Trodelvy label expansion risk as key clinical milestones
ABBV may suit investors who:
- →prefer AbbVie's successful Humira transition to Skyrizi and Rinvoq as two of the most successful immunology drug launches ever
- →value Botox aesthetics as consumer healthcare revenue diversification that is partially uncorrelated with drug patent cliffs
- →want a large-cap biopharma income investment with 3%+ dividend yield supported by immunology franchise cash flows
- →are comfortable with Humira biosimilar erosion continuing and Skyrizi/Rinvoq facing competition from next-generation immunology drugs
Performance & AI score
| Metric | GILD | ABBV |
|---|---|---|
| AI score | 41.3 | 52.0 |
| AI rank | #967 | #346 |
| Latest close | $123.76 | $216.49 |
| 1M return | -5.16% | +1.28% |
| 6M return | +1.98% | -3.49% |
| 1Y return | +14.59% | +16.72% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | GILD | ABBV |
|---|---|---|
| 1Y ago | $11.46K (+14.6%) started 2025-06-18 | $11.67K (+16.7%) started 2025-06-18 |
| 5Y ago | $25.04K (+150.4%) started 2021-06-21 | $26.07K (+160.7%) started 2021-06-21 |
| 10Y ago | $29.99K (+199.9%) started 2016-06-20 | $83.39K (+733.9%) started 2016-06-20 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | GILD | ABBV |
|---|---|---|
| Market cap | $153.66B | $382.49B |
| Trailing P/E | 16.84 | 106.12 |
| Forward P/E | 12.80 | 13.32 |
| Price/Sales | 4.87 | 5.85 |
| EV/Revenue | 5.58 | 7.10 |
| Analyst target | $157.57 | $253.55 |
| Target upside | +27.32% | +17.12% |
Growth, profitability & risk
| Metric | GILD | ABBV |
|---|---|---|
| Revenue growth | 4.40% | 12.40% |
| Earnings growth | 54.80% | -46.20% |
| EPS growth | +54.80% | -46.20% |
| FCF margin | +26.68% | +33.13% |
| Operating margin | 39.28% | 32.16% |
| Profit margin | 30.99% | 5.79% |
| ROIC proxy | 43.36% | 6225.00% |
| Return on equity | 43.36% | 6225.00% |
| Dividend yield | 2.65% | 3.20% |
| Beta | 0.33 | 0.31 |
| Debt/equity | 94.64 | 4789.60 |
| Current ratio | 1.97 | 0.80 |
| Quick ratio | 1.54 | 0.52 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
GILD max drawdown22.03%
ABBV max drawdown19.23%
GILD max wkly drop5.98%
ABBV max wkly drop8.49%
5Y risk snapshot
GILD max drawdown26.59%
ABBV max drawdown21.92%
GILD max wkly drop9.78%
ABBV max wkly drop17.30%
10Y risk snapshot
GILD max drawdown30.47%
ABBV max drawdown45.09%
GILD max wkly drop12.29%
ABBV max wkly drop19.39%
Performance metrics by period
| Period | Metric | GILD | ABBV |
|---|---|---|---|
| 1Y | Growth | +14.59% | +16.71% |
| CAGR | +14.61% | +16.74% | |
| Sharpe ratio | 0.48 | 0.57 | |
| Max drawdown | 22.03% | 19.23% | |
| Max daily drop | 4.28% | 5.20% | |
| Max wkly drop | 5.98% | 8.49% | |
| 5Y | Growth | +113.43% | +120.43% |
| CAGR | +16.40% | +17.16% | |
| Sharpe ratio | 0.56 | 0.61 | |
| Max drawdown | 26.59% | 21.92% | |
| Max daily drop | 10.15% | 12.57% | |
| Max wkly drop | 9.78% | 17.30% | |
| 10Y | Growth | +105.64% | +426.67% |
| CAGR | +7.48% | +18.09% | |
| Sharpe ratio | 0.23 | 0.60 | |
| Max drawdown | 30.47% | 45.09% | |
| Max daily drop | 10.15% | 16.25% | |
| Max wkly drop | 12.29% | 19.39% |
Business comparison
| Category | GILD | ABBV |
|---|---|---|
| Company | Gilead Sciences, Inc. | AbbVie Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Core business | Gilead Sciences is a biopharmaceutical company focused on antiviral medications, oncology, and inflammation. Its antiviral franchise includes Biktarvy (HIV), Veklury (remdesivir for COVID), and hepatitis C treatments. Gilead's oncology portfolio (Trodelvy, Yescarta CAR-T) is a growing revenue driver as the company diversifies beyond antivirals. Gilead also acquired CymaBay (liver disease) and has MASH pipeline assets. The company pays a substantial dividend supported by its antiviral cash flows. | AbbVie is one of the world's largest biopharmaceutical companies, historically dependent on Humira (adalimumab) which lost US market exclusivity in early 2023. Its immunology successors Skyrizi (risankizumab, IL-23) and Rinvoq (upadacitinib, JAK1) are growing rapidly across multiple immune-mediated diseases and collectively generate $15B+ in annual revenue. AbbVie's aesthetics business (Botox via Allergan acquisition) provides consumer-facing revenue diversification. A substantial dividend (3%+ yield) is supported by immunology cash flows. |
| Investor focus | Investors track Biktarvy HIV revenue sustainability, Trodelvy oncology label expansion, CAR-T (Yescarta/Tecartus) revenue growth, MASH pipeline progress, and dividend sustainability from antiviral cash flows. | Investors track Skyrizi and Rinvoq combined revenue growth across psoriasis, IBD, atopic dermatitis, and rheumatoid arthritis, Botox aesthetic revenue in consumer healthcare, Humira biosimilar market share erosion pace, and dividend sustainability. |
GILD strengths
- →Biktarvy is the most prescribed HIV regimen globally, generating $12B+ annually with high patient adherence and switching costs
- →Trodelvy ADC (antibody-drug conjugate) is FDA-approved in multiple cancer types with additional label expansion ongoing
- →Strong balance sheet and antiviral cash flows support both dividend payments and M&A to diversify the oncology pipeline
ABBV strengths
- →Skyrizi and Rinvoq are two of the most successful immunology drug launches in history, collectively growing faster than Humira's peak revenue
- →Allergan aesthetics (Botox, Juvederm) provides consumer healthcare diversification that is more recession-resistant than pure biotech revenue
- →Deep immunology expertise and JAK/IL-23 mechanisms cover a broad range of immune diseases, enabling label expansions across many conditions
Risks to watch — GILD
- →HIV market faces long-acting injectable competition from ViiV Healthcare (Cabenuva/Cabotegravir) that could erode Biktarvy's share
- →Oncology pipeline milestones (Trodelvy in lung, bladder, other cancers) are critical to sustaining post-antiviral revenue growth
- →Hepatitis C revenues have declined dramatically from peak — this legacy revenue stream continues to shrink
Risks to watch — ABBV
- →Humira biosimilar erosion is underway and will continue reducing the Humira revenue contribution over the next several years
- →Skyrizi and Rinvoq face competition from new IL-23, IL-17, and JAK inhibitors from Novartis, UCB, and Lilly
- →Botox aesthetics revenue is sensitive to consumer spending cycles and faces competition from biosimilar Botox (Jeuveau, Dysport)
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Related comparisons
ABBV vs BMY
Which Pharma Value Stock Is Better?
MRK vs ABBV
Oncology Leader vs Immunology Giant
JNJ vs ABBV
Diversified MedTech vs Immunology Powerhouse
AMGN vs ABBV
Which Biotech/Pharma Dividend Stock Wins?
ABBV vs JNJ
Which Pharma Dividend Stock Is Better?
GILD vs MRK
Antiviral Specialist vs Keytruda Blockbuster Giant
More comparisons
Browse all 1,000 comparisons →